Ranolazine in patients with angina and coronary artery disease

Current Cardiology Reports

Volumn 9, Issue 4, 2007, Pages 272-278

  Scirica, Benjamin M ^a   Morrow, David A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; FASUDIL; GLYCERYL TRINITRATE; IVABRADINE; KETOCONAZOLE; MACROLIDE; NICORANDIL; NIFEDIPINE; NITRIC ACID DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; RANOLAZINE; SIMVASTATIN; TRIMETAZIDINE; VERAPAMIL;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXERCISE TOLERANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; HYPOTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; QT PROLONGATION; REVIEW; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; STRUCTURE ANALYSIS; SYNCOPE; TREADMILL EXERCISE; WEAKNESS;

ACETANILIDES; ANGINA PECTORIS; CORONARY ARTERIOSCLEROSIS; ENZYME INHIBITORS; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 34447502228     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938375     Document Type: Review

References (28)

1. Thom T, Haase N, Rosamond W, et al.: Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.
2. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). Available at http://www.acc.org/qualityandscience/clinical/ guidelines/stable/update_index.htm.
3. Mukherjee D, Bhatt DL, Roe MT, et al.: Direct myocardial revascularization and angiogenesis--how many patients might be eligible? Am J Cardiol 1999, 84:598-600.
4. Camici PG, Crea F: Coronary microvascular dysfunction. N Engl J Med 2007, 356:830-840.
5. Reis SE, Holubkov R, Conrad Smith AJ, et al.: Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001, 141:735-741.
6. Abrams J: Clinical practice. Chronic stable angina. N Engl J Med 2005, 352:2524-2533.
7. Abrams J, Thadani U: Therapy of stable angina pectoris: the uncomplicated patient. Circulation 2005, 112:e255-e259.
8. Smith SC Jr, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
9. Cannon CP, Steinberg BA, Murphy SA, et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438-445.
10. Hambrecht R, Adams V, Erbs S, et al.: Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 2003, 107:3152-3158.
11. Heidenreich PA, McDonald KM, Hastie T, et al.: Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999, 281:1927-1936.
12. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003, 41:159-168.
13. Boden WE, O'Rourke RA, Teo KK, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503-1516.
14. Chaitman BR: Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113:2462-2472.
15. Belardinelli L, Shryock JC, Fraser H: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(Suppl 4):iv6-iv14.
16. Antzelevitch C, Belardinelli L, Zygmunt AC, et al.: Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110:904-910.
17. Chaitman BR, Skettino SL, Parker JO, et al.: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
18. Chaitman BR, Pepine CJ, Parker JO, et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004 291:309-316.
19. Timmis AD, Chaitman BR, Crager M: Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006, 27:42-48.
20. Stone PH, Gratsiansky NA, Blokhin A, et al.: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006, 48:566-575.
21. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.: Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006, 151:1186; e1181-e1189.
22. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007, 297:1775-1783.
23. Koren MJ, Crager MR, Sweeney M: Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007, 49:1027-1034.
24. Borer JS, Fox K, Jaillon P, et al.: Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107:817-823.
25. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002, 359:1269-1275.
26. Vicari RM, Chaitman B, Keefe D, et al.: Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005, 46:1803-1811.
27. Manchanda SC, Krishnaswami S: Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997, 78:353-357.
28. Marzilli M, Klein WW: Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003, 14:171-179.